Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Supply, Demand and Key Producers, 2023-2029

Table of Contents

1 Supply Summary_x000D_
    1.1 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction_x000D_
    1.2 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size & Forecast (2018 & 2022 & 2029)_x000D_
    1.3 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Total Market by Region (by Headquarter Location)_x000D_
        1.3.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region (2018-2029), (by Headquarter Location)_x000D_
        1.3.2 United States Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.4 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.5 Japan Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.6 South Korea Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.7 ASEAN Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
        1.3.8 India Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029)_x000D_
    1.4 Market Drivers, Restraints and Trends_x000D_
        1.4.1 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Drivers_x000D_
        1.4.2 Factors Affecting Demand_x000D_
        1.4.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Major Market Trends_x000D_
    1.5 Influence of COVID-19 and Russia-Ukraine War_x000D_
        1.5.1 Influence of COVID-19_x000D_
        1.5.2 Influence of Russia-Ukraine War_x000D_
2 Demand Summary_x000D_
    2.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.2 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value by Region_x000D_
        2.2.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value by Region (2018-2023)_x000D_
        2.2.2 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value Forecast by Region (2024-2029)_x000D_
    2.3 United States Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.4 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.5 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.6 Japan Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.7 South Korea Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.8 ASEAN Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
    2.9 India Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value (2018-2029)_x000D_
3 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies Competitive Analysis_x000D_
    3.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue by Player (2018-2023)_x000D_
    3.2 Industry Rank and Concentration Rate (CR)_x000D_
        3.2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Industry Rank of Major Players_x000D_
        3.2.2 Global Concentration Ratios (CR4) for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) in 2022_x000D_
        3.2.3 Global Concentration Ratios (CR8) for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) in 2022_x000D_
    3.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Company Evaluation Quadrant_x000D_
    3.4 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market: Overall Company Footprint Analysis_x000D_
        3.4.1 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market: Region Footprint_x000D_
        3.4.2 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market: Company Product Type Footprint_x000D_
        3.4.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market: Company Product Application Footprint_x000D_
    3.5 Competitive Environment_x000D_
        3.5.1 Historical Structure of the Industry_x000D_
        3.5.2 Barriers of Market Entry_x000D_
        3.5.3 Factors of Competition_x000D_
    3.6 Mergers, Acquisitions Activity_x000D_
4 United States VS China VS Rest of the World (by Headquarter Location)_x000D_
    4.1 United States VS China: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue Comparison (by Headquarter Location)_x000D_
        4.1.1 United States VS China: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)_x000D_
        4.1.2 United States VS China: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue Market Share Comparison (2018 & 2022 & 2029)_x000D_
    4.2 United States Based Companies VS China Based Companies: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value Comparison_x000D_
        4.2.1 United States VS China: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value Comparison (2018 & 2022 & 2029)_x000D_
        4.2.2 United States VS China: Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Consumption Value Market Share Comparison (2018 & 2022 & 2029)_x000D_
    4.3 United States Based Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies and Market Share, 2018-2023_x000D_
        4.3.1 United States Based Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies, Headquarters (States, Country)_x000D_
        4.3.2 United States Based Companies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, (2018-2023)_x000D_
    4.4 China Based Companies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue and Market Share, 2018-2023_x000D_
        4.4.1 China Based Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies, Company Headquarters (Province, Country)_x000D_
        4.4.2 China Based Companies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, (2018-2023)_x000D_
    4.5 Rest of World Based Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies and Market Share, 2018-2023_x000D_
        4.5.1 Rest of World Based Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Companies, Headquarters (States, Country)_x000D_
        4.5.2 Rest of World Based Companies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, (2018-2023)_x000D_
5 Market Analysis by Type_x000D_
    5.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Overview by Type: 2018 VS 2022 VS 2029_x000D_
    5.2 Segment Introduction by Type_x000D_
        5.2.1 Intermediate CDMO_x000D_
        5.2.2 API CDMO_x000D_
        5.2.3 Formulation CDMO_x000D_
        5.2.4 Protein CDMO_x000D_
        5.2.5 Gene Therapy CDMO_x000D_
        5.2.6 Cell Therapy CDMO_x000D_
    5.3 Market Segment by Type_x000D_
        5.3.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023)_x000D_
        5.3.2 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029)_x000D_
        5.3.3 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Market Share by Type (2018-2029)_x000D_
6 Market Analysis by Application_x000D_
    6.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Overview by Application: 2018 VS 2022 VS 2029_x000D_
    6.2 Segment Introduction by Application_x000D_
        6.2.1 Pharmaceutical Company_x000D_
        6.2.2 Biotechnology Company_x000D_
        6.2.3 Generic Company_x000D_
        6.2.4 Others_x000D_
        6.2.5 Others_x000D_
    6.3 Market Segment by Application_x000D_
        6.3.1 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023)_x000D_
        6.3.2 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029)_x000D_
        6.3.3 World Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2029)_x000D_
7 Company Profiles_x000D_
    7.1 Lonza_x000D_
        7.1.1 Lonza Details_x000D_
        7.1.2 Lonza Major Business_x000D_
        7.1.3 Lonza Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.1.4 Lonza Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.1.5 Lonza Recent Developments/Updates_x000D_
        7.1.6 Lonza Competitive Strengths & Weaknesses_x000D_
    7.2 Catalent_x000D_
        7.2.1 Catalent Details_x000D_
        7.2.2 Catalent Major Business_x000D_
        7.2.3 Catalent Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.2.4 Catalent Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.2.5 Catalent Recent Developments/Updates_x000D_
        7.2.6 Catalent Competitive Strengths & Weaknesses_x000D_
    7.3 Patheon (Thermo Fisher Scientific)_x000D_
        7.3.1 Patheon (Thermo Fisher Scientific) Details_x000D_
        7.3.2 Patheon (Thermo Fisher Scientific) Major Business_x000D_
        7.3.3 Patheon (Thermo Fisher Scientific) Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.3.4 Patheon (Thermo Fisher Scientific) Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.3.5 Patheon (Thermo Fisher Scientific) Recent Developments/Updates_x000D_
        7.3.6 Patheon (Thermo Fisher Scientific) Competitive Strengths & Weaknesses_x000D_
    7.4 Aenova_x000D_
        7.4.1 Aenova Details_x000D_
        7.4.2 Aenova Major Business_x000D_
        7.4.3 Aenova Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.4.4 Aenova Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.4.5 Aenova Recent Developments/Updates_x000D_
        7.4.6 Aenova Competitive Strengths & Weaknesses_x000D_
    7.5 Siegfried_x000D_
        7.5.1 Siegfried Details_x000D_
        7.5.2 Siegfried Major Business_x000D_
        7.5.3 Siegfried Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.5.4 Siegfried Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.5.5 Siegfried Recent Developments/Updates_x000D_
        7.5.6 Siegfried Competitive Strengths & Weaknesses_x000D_
    7.6 Recipharm_x000D_
        7.6.1 Recipharm Details_x000D_
        7.6.2 Recipharm Major Business_x000D_
        7.6.3 Recipharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.6.4 Recipharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.6.5 Recipharm Recent Developments/Updates_x000D_
        7.6.6 Recipharm Competitive Strengths & Weaknesses_x000D_
    7.7 Strides Shasun_x000D_
        7.7.1 Strides Shasun Details_x000D_
        7.7.2 Strides Shasun Major Business_x000D_
        7.7.3 Strides Shasun Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.7.4 Strides Shasun Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.7.5 Strides Shasun Recent Developments/Updates_x000D_
        7.7.6 Strides Shasun Competitive Strengths & Weaknesses_x000D_
    7.8 Piramal_x000D_
        7.8.1 Piramal Details_x000D_
        7.8.2 Piramal Major Business_x000D_
        7.8.3 Piramal Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.8.4 Piramal Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.8.5 Piramal Recent Developments/Updates_x000D_
        7.8.6 Piramal Competitive Strengths & Weaknesses_x000D_
    7.9 Metrics_x000D_
        7.9.1 Metrics Details_x000D_
        7.9.2 Metrics Major Business_x000D_
        7.9.3 Metrics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.9.4 Metrics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.9.5 Metrics Recent Developments/Updates_x000D_
        7.9.6 Metrics Competitive Strengths & Weaknesses_x000D_
    7.10 AMRI_x000D_
        7.10.1 AMRI Details_x000D_
        7.10.2 AMRI Major Business_x000D_
        7.10.3 AMRI Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.10.4 AMRI Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.10.5 AMRI Recent Developments/Updates_x000D_
        7.10.6 AMRI Competitive Strengths & Weaknesses_x000D_
    7.11 Famar_x000D_
        7.11.1 Famar Details_x000D_
        7.11.2 Famar Major Business_x000D_
        7.11.3 Famar Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.11.4 Famar Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.11.5 Famar Recent Developments/Updates_x000D_
        7.11.6 Famar Competitive Strengths & Weaknesses_x000D_
    7.12 WuXi AppTech_x000D_
        7.12.1 WuXi AppTech Details_x000D_
        7.12.2 WuXi AppTech Major Business_x000D_
        7.12.3 WuXi AppTech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.12.4 WuXi AppTech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.12.5 WuXi AppTech Recent Developments/Updates_x000D_
        7.12.6 WuXi AppTech Competitive Strengths & Weaknesses_x000D_
    7.13 Asymchem_x000D_
        7.13.1 Asymchem Details_x000D_
        7.13.2 Asymchem Major Business_x000D_
        7.13.3 Asymchem Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.13.4 Asymchem Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.13.5 Asymchem Recent Developments/Updates_x000D_
        7.13.6 Asymchem Competitive Strengths & Weaknesses_x000D_
    7.14 Porton_x000D_
        7.14.1 Porton Details_x000D_
        7.14.2 Porton Major Business_x000D_
        7.14.3 Porton Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.14.4 Porton Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.14.5 Porton Recent Developments/Updates_x000D_
        7.14.6 Porton Competitive Strengths & Weaknesses_x000D_
    7.15 Amatsigroup_x000D_
        7.15.1 Amatsigroup Details_x000D_
        7.15.2 Amatsigroup Major Business_x000D_
        7.15.3 Amatsigroup Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.15.4 Amatsigroup Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.15.5 Amatsigroup Recent Developments/Updates_x000D_
        7.15.6 Amatsigroup Competitive Strengths & Weaknesses_x000D_
    7.16 AcuraBio_x000D_
        7.16.1 AcuraBio Details_x000D_
        7.16.2 AcuraBio Major Business_x000D_
        7.16.3 AcuraBio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.16.4 AcuraBio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.16.5 AcuraBio Recent Developments/Updates_x000D_
        7.16.6 AcuraBio Competitive Strengths & Weaknesses_x000D_
    7.17 Moravek_x000D_
        7.17.1 Moravek Details_x000D_
        7.17.2 Moravek Major Business_x000D_
        7.17.3 Moravek Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.17.4 Moravek Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.17.5 Moravek Recent Developments/Updates_x000D_
        7.17.6 Moravek Competitive Strengths & Weaknesses_x000D_
    7.18 Ascendia Pharmaceuticals_x000D_
        7.18.1 Ascendia Pharmaceuticals Details_x000D_
        7.18.2 Ascendia Pharmaceuticals Major Business_x000D_
        7.18.3 Ascendia Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.18.4 Ascendia Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.18.5 Ascendia Pharmaceuticals Recent Developments/Updates_x000D_
        7.18.6 Ascendia Pharmaceuticals Competitive Strengths & Weaknesses_x000D_
    7.19 Ardena_x000D_
        7.19.1 Ardena Details_x000D_
        7.19.2 Ardena Major Business_x000D_
        7.19.3 Ardena Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.19.4 Ardena Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.19.5 Ardena Recent Developments/Updates_x000D_
        7.19.6 Ardena Competitive Strengths & Weaknesses_x000D_
    7.20 CPL_x000D_
        7.20.1 CPL Details_x000D_
        7.20.2 CPL Major Business_x000D_
        7.20.3 CPL Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.20.4 CPL Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.20.5 CPL Recent Developments/Updates_x000D_
        7.20.6 CPL Competitive Strengths & Weaknesses_x000D_
    7.21 Arranta Bio_x000D_
        7.21.1 Arranta Bio Details_x000D_
        7.21.2 Arranta Bio Major Business_x000D_
        7.21.3 Arranta Bio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.21.4 Arranta Bio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.21.5 Arranta Bio Recent Developments/Updates_x000D_
        7.21.6 Arranta Bio Competitive Strengths & Weaknesses_x000D_
    7.22 UPM Pharmaceuticals_x000D_
        7.22.1 UPM Pharmaceuticals Details_x000D_
        7.22.2 UPM Pharmaceuticals Major Business_x000D_
        7.22.3 UPM Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.22.4 UPM Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.22.5 UPM Pharmaceuticals Recent Developments/Updates_x000D_
        7.22.6 UPM Pharmaceuticals Competitive Strengths & Weaknesses_x000D_
    7.23 FUJIFILM Diosynth Biotechnologies_x000D_
        7.23.1 FUJIFILM Diosynth Biotechnologies Details_x000D_
        7.23.2 FUJIFILM Diosynth Biotechnologies Major Business_x000D_
        7.23.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.23.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.23.5 FUJIFILM Diosynth Biotechnologies Recent Developments/Updates_x000D_
        7.23.6 FUJIFILM Diosynth Biotechnologies Competitive Strengths & Weaknesses_x000D_
    7.24 Groupe Parima_x000D_
        7.24.1 Groupe Parima Details_x000D_
        7.24.2 Groupe Parima Major Business_x000D_
        7.24.3 Groupe Parima Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.24.4 Groupe Parima Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.24.5 Groupe Parima Recent Developments/Updates_x000D_
        7.24.6 Groupe Parima Competitive Strengths & Weaknesses_x000D_
    7.25 TBD Pharmatech_x000D_
        7.25.1 TBD Pharmatech Details_x000D_
        7.25.2 TBD Pharmatech Major Business_x000D_
        7.25.3 TBD Pharmatech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.25.4 TBD Pharmatech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.25.5 TBD Pharmatech Recent Developments/Updates_x000D_
        7.25.6 TBD Pharmatech Competitive Strengths & Weaknesses_x000D_
    7.26 Avid Bioservices_x000D_
        7.26.1 Avid Bioservices Details_x000D_
        7.26.2 Avid Bioservices Major Business_x000D_
        7.26.3 Avid Bioservices Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.26.4 Avid Bioservices Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.26.5 Avid Bioservices Recent Developments/Updates_x000D_
        7.26.6 Avid Bioservices Competitive Strengths & Weaknesses_x000D_
    7.27 Vetter Pharma_x000D_
        7.27.1 Vetter Pharma Details_x000D_
        7.27.2 Vetter Pharma Major Business_x000D_
        7.27.3 Vetter Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.27.4 Vetter Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.27.5 Vetter Pharma Recent Developments/Updates_x000D_
        7.27.6 Vetter Pharma Competitive Strengths & Weaknesses_x000D_
    7.28 NextPharma_x000D_
        7.28.1 NextPharma Details_x000D_
        7.28.2 NextPharma Major Business_x000D_
        7.28.3 NextPharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.28.4 NextPharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.28.5 NextPharma Recent Developments/Updates_x000D_
        7.28.6 NextPharma Competitive Strengths & Weaknesses_x000D_
    7.29 Alcami_x000D_
        7.29.1 Alcami Details_x000D_
        7.29.2 Alcami Major Business_x000D_
        7.29.3 Alcami Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.29.4 Alcami Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.29.5 Alcami Recent Developments/Updates_x000D_
        7.29.6 Alcami Competitive Strengths & Weaknesses_x000D_
    7.30 NerPharMa_x000D_
        7.30.1 NerPharMa Details_x000D_
        7.30.2 NerPharMa Major Business_x000D_
        7.30.3 NerPharMa Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.30.4 NerPharMa Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.30.5 NerPharMa Recent Developments/Updates_x000D_
        7.30.6 NerPharMa Competitive Strengths & Weaknesses_x000D_
    7.31 Vetio_x000D_
        7.31.1 Vetio Details_x000D_
        7.31.2 Vetio Major Business_x000D_
        7.31.3 Vetio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.31.4 Vetio Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.31.5 Vetio Recent Developments/Updates_x000D_
        7.31.6 Vetio Competitive Strengths & Weaknesses_x000D_
    7.32 Societal CDMO_x000D_
        7.32.1 Societal CDMO Details_x000D_
        7.32.2 Societal CDMO Major Business_x000D_
        7.32.3 Societal CDMO Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.32.4 Societal CDMO Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.32.5 Societal CDMO Recent Developments/Updates_x000D_
        7.32.6 Societal CDMO Competitive Strengths & Weaknesses_x000D_
    7.33 ten23 health_x000D_
        7.33.1 ten23 health Details_x000D_
        7.33.2 ten23 health Major Business_x000D_
        7.33.3 ten23 health Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.33.4 ten23 health Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.33.5 ten23 health Recent Developments/Updates_x000D_
        7.33.6 ten23 health Competitive Strengths & Weaknesses_x000D_
    7.34 Piramal Pharma Solutions_x000D_
        7.34.1 Piramal Pharma Solutions Details_x000D_
        7.34.2 Piramal Pharma Solutions Major Business_x000D_
        7.34.3 Piramal Pharma Solutions Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.34.4 Piramal Pharma Solutions Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.34.5 Piramal Pharma Solutions Recent Developments/Updates_x000D_
        7.34.6 Piramal Pharma Solutions Competitive Strengths & Weaknesses_x000D_
    7.35 MedPharm_x000D_
        7.35.1 MedPharm Details_x000D_
        7.35.2 MedPharm Major Business_x000D_
        7.35.3 MedPharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.35.4 MedPharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.35.5 MedPharm Recent Developments/Updates_x000D_
        7.35.6 MedPharm Competitive Strengths & Weaknesses_x000D_
    7.36 Lundbeck_x000D_
        7.36.1 Lundbeck Details_x000D_
        7.36.2 Lundbeck Major Business_x000D_
        7.36.3 Lundbeck Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.36.4 Lundbeck Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.36.5 Lundbeck Recent Developments/Updates_x000D_
        7.36.6 Lundbeck Competitive Strengths & Weaknesses_x000D_
    7.37 AGC Pharma Chemicals_x000D_
        7.37.1 AGC Pharma Chemicals Details_x000D_
        7.37.2 AGC Pharma Chemicals Major Business_x000D_
        7.37.3 AGC Pharma Chemicals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.37.4 AGC Pharma Chemicals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.37.5 AGC Pharma Chemicals Recent Developments/Updates_x000D_
        7.37.6 AGC Pharma Chemicals Competitive Strengths & Weaknesses_x000D_
    7.38 BioVectra_x000D_
        7.38.1 BioVectra Details_x000D_
        7.38.2 BioVectra Major Business_x000D_
        7.38.3 BioVectra Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.38.4 BioVectra Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.38.5 BioVectra Recent Developments/Updates_x000D_
        7.38.6 BioVectra Competitive Strengths & Weaknesses_x000D_
    7.39 Pfizer CentreOne_x000D_
        7.39.1 Pfizer CentreOne Details_x000D_
        7.39.2 Pfizer CentreOne Major Business_x000D_
        7.39.3 Pfizer CentreOne Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.39.4 Pfizer CentreOne Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue, Gross Margin and Market Share (2018-2023)_x000D_
        7.39.5 Pfizer CentreOne Recent Developments/Updates_x000D_
        7.39.6 Pfizer CentreOne Competitive Strengths & Weaknesses_x000D_
    7.40 Jubilant Biosys_x000D_
        7.40.1 Jubilant Biosys Details_x000D_
        7.40.2 Jubilant Biosys Major Business_x000D_
        7.40.3 Jubilant Biosys Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Product and Services_x000D_
        7.40.4 Jubilant Biosys Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) R